Developing a new drug is often like finding a needle in a haystack. Scientists identify a protein linked to disease, then search through vast chemical libraries hoping to find a molecule that binds to it — a process that is costly, slow, and often unsuccessful.

Now, researchers at the Korea Advanced Institute of Science and Technology (KAIST) have introduced a game-changing approach. Their new AI model, BInD — short for Bond and Interaction-Generating Diffusion Model — can design drug candidates using only the 3D structure of the target protein, without needing any prior information about known binding molecules (Lee, Zhung, Seo, & Kim, 2025).

How BInD Changes the Game

Most AI systems either:

  1. Generate possible drug molecules and then check if they can bind to a target, or
  2. Predict how existing molecules might interact with a protein.

BInD does both at once — creating molecules  and modeling how they will interact with the target protein during the same design process.

It starts with a random molecular structure and gradually refines it using a diffusion-based process. What makes it unique is that it follows real chemical rules from the start — including bond lengths, protein-ligand distances, and the patterns of non-covalent interactions that are essential for strong binding (Lee et al., 2025).

And unlike many models that focus on just one or two design goals, BInD optimizes for several at the same time:

  • Strong binding affinity to the target protein
  • Structural stability
  • Drug-like properties suitable for development

Why This Matters for Cancer Research

In early tests, BInD successfully designed molecules that selectively bind to mutated forms of EGFR — a protein often linked to cancer growth (KAIST, 2025). This selective targeting is crucial, as it could lead to treatments that are more effective and cause fewer side effects.

According to lead researcher Professor Woo Youn Kim, this technology “could significantly shift the paradigm of drug development” by eliminating much of the trial-and-error process and speeding up the path from concept to viable drug candidate (KAIST, 2025).

The Bigger Picture for Drug Development Professionals

For those working in medicines development, BInD is more than just a research breakthrough — it reflects the kind of digital innovation that is reshaping the industry:

  • Applying AI in medicines development to accelerate discovery and improve decision-making.
  • Leveraging big data and real-world evidence to guide candidate selection and design strategies.
  • Integrating digital health technologies to improve patient engagement and optimize trial efficiency.

GMDP Academy’s Module 8: Digital Technology in Medicines Development provides the skills to navigate these transformations, equipping professionals to evaluate, adopt, and apply emerging technologies like BInD in real-world settings.

References

KAIST. (2025, August 11). AI automatically designs optimal drug candidates for cancer-targeting mutations. Phys.org. https://phys.org/news/2025-08-ai-automatically-optimal-drug-candidates.html

Lee, J., Zhung, W., Seo, J., & Kim, W. Y. (2025). BInD: Bond and interaction-generating diffusion model for multi-objective structure-based drug design. Advanced Science. Advance online publication. https://doi.org/10.1002/advs.202502702

Disclaimers

  • The material in these reviews is from various public open-access sources, meant for educational and informational purposes only
  • Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
  • No official support by any organization(s) has been provided or should be inferred